Format

Send to

Choose Destination
Neurosurg Rev. 2017 Jul;40(3):449-460. doi: 10.1007/s10143-016-0802-z. Epub 2016 Nov 17.

Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years.

Author information

1
Department of Neurosurgery, Oslo University Hospital - Rikshospitalet, 4950 Nydalen, Oslo, 0424, Norway. m.s.s.konig@medisin.uio.no.
2
Department of Neurology, Ostfold Hospital Trust, 300, Gralum, 1714, Norway. m.s.s.konig@medisin.uio.no.
3
Institute of Clinical Medicine, University of Oslo, 1711 Blindern, Oslo, 0318, Norway. m.s.s.konig@medisin.uio.no.
4
Institute of Clinical Medicine, University of Oslo, 1711 Blindern, Oslo, 0318, Norway.
5
Department of Otorhinolaryngology, Oslo University Hospital - Rikshospitalet, 4950 Nydalen, 0424, Oslo, Norway.
6
Department of Pathology, Oslo University Hospital - Radiumhospitalet, 4950 Nydalen, Oslo, 0424, Norway.
7
Department of Oncology, Oslo University Hospital - Radiumhospitalet, 4950 Nydalen, Oslo, 0424, Norway.
8
Department of Neurosurgery, Oslo University Hospital - Rikshospitalet, 4950 Nydalen, Oslo, 0424, Norway.

Abstract

High-grade craniofacial osteosarcoma (CFOS) is an aggressive malignancy with a poor prognosis. Our goals were to evaluate treatment outcomes in those treated at a single referral institution over 35 years and to compare our results to the available literature. A retrospective analysis of all 42 patients treated between 1980 and 2015 at Oslo University Hospital, Norway, identified in a prospectively collected database, was conducted. Mean follow-up was 79.6 months. Overall survival at 2 and 5 years was 70.5 and 44.7%, respectively. The corresponding disease-specific survival rates were 73.0 and 49.8%. Treatment was surgery only in eight cases. Additional therapy was administered in 34 patients: chemotherapy in nine, radiotherapy in seven, and a combination of these in 18 cases. Stratified analysis by resection margins demonstrated significantly better survival at 2 and 5 years after radical surgical treatment. Neoadjuvant chemotherapy and subsequent adequate surgery resulted in better survival than surgery alone. Half of the patients either had a primary or familial cancer predisposition. This is the largest single-center study conducted on high-grade CFOS to date. Our experience indicates that neoadjuvant chemotherapy with complete surgical resection significantly improved survival, compared to surgery alone.

KEYWORDS:

Craniofacial bones; Multidisciplinary approach; Multimodal treatment; Osteosarcoma; Surgical resection; Survival

PMID:
27858303
DOI:
10.1007/s10143-016-0802-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer Icon for Norwegian BIBSYS system
Loading ...
Support Center